Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldafermin - NGM Biopharmaceuticals

Drug Profile

Aldafermin - NGM Biopharmaceuticals

Alternative Names: M 52; NGM 282

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Laxatives; Recombinant proteins
  • Mechanism of Action FGF19 protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis; Primary biliary cirrhosis
  • New Molecular Entity No
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Phase II Diarrhoea; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
  • No development reported Constipation; Type 2 diabetes mellitus

Most Recent Events

  • 11 Mar 2024 NGM Biopharmaceuticals plans a registrational phase II trial for Primary Sclerosing Cholangitis in 2024
  • 09 Jan 2024 Aldafermin is still in phase II trials for Primary sclerosing cholangitis (Monotherapy, Combination therapy) in the US, United Kingdom, Netherlands, France
  • 10 Nov 2023 Efficacy and adverse event data from a phase IIb ALPINE 4 trial in Non alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top